Thursday, October 23, 2014 12:23:39 AM
"A successful ALS drug must show effects over a year or more so that short term results must be viewed with caution."
Where is he getting that? That is not true. So far the data on NurOwn suggests that the effects wear off after about 3 months or so, so they'll need to re-dose 3 or 4 times a year. That doesn't mean it isn't successful.
"Recently there have been two large trials in ALS involving Biogen’s dexpramipexole and Cytokinetic’s tirasemtiv. Neither drug was successful in showing a statistically significant improvement in ALSFRS-r in large randomized trials involving several hundred patients. Hence a statistically significant improvement in a 12 patient randomized trial would be stunning."
I think this is a meaningless statement. It wouldn't be stunning if the drug actually worked. Biogen and Cytokinetic's drug failed because it just didn't work. Especially if you are working with stem cells like BCLI and CUR, where you can't tell the cells not to do their job from the beginning.
I do agree with the points about not showing placebo results and that making this data difficult to interpret clearly. Why have a placebo arm if you aren't going to compare those who were treated with it? It brings the entirety of the data into question in my opinion.
Recent BCLI News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 10:00:11 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:00:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 11:53:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 11:41:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 01:14:17 PM
- BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference • PR Newswire (US) • 02/27/2024 11:30:00 AM
- BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS • PR Newswire (US) • 02/23/2024 11:00:00 AM
- BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum • PR Newswire (US) • 02/13/2024 11:30:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 03:06:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 10:04:29 PM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 12/18/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 12/04/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 11/28/2023 10:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/22/2023 09:00:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 11:03:08 AM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 11/21/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 11/14/2023 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:01:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/08/2023 10:28:04 PM
- The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) • PR Newswire (US) • 11/07/2023 06:57:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 08:07:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 11:30:11 AM
- Biotech Shares Halted Premarket As FDA Reviews Application • AllPennyStocks.com • 09/27/2023 02:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2023 09:16:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:31:22 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM